Algernon Health Inc (AGN-CN) Stock Price and News - The Globe and Mail

Top Stories: Algernon Health Inc

Algernon Announces Additional Increase to Private Placement Financing to $858,000 and Final Closing of the Financing

December 31, 2025

Algernon Announces Increase to Private Placement Financing to $750,000 and Close of Third Tranche

December 23, 2025

Algernon Closes Second Tranche of Private Placement Financing

November 28, 2025

Algernon Health and American Molecular Imaging Announce Strategic Business and USD $500K Investment Agreement

November 17, 2025

Algernon Closes First Tranche of its Recently Announced Private Placement Financing

November 14, 2025

Algernon Health Announces Private Placement

November 6, 2025

Algernon Pharmaceuticals Completes Name Change to Algernon Health

October 15, 2025

Algernon Announces Preferred Share Class Approved at Annual and Special Meeting

September 19, 2025

Algernon Pharmaceuticals Announces Name Change to Algernon Health

September 4, 2025

Algernon Announces Closing of the Private Placement Financing

Algernon Announces Warrant Extension

Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease

Algernon NeuroScience Engages Netcapital Securities for Planned Regulation A Financing

Algernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke Study

February 11, 2025

Algernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease Patent

January 6, 2025

Algernon Announces Warrant Extension

November 4, 2024

Algernon Pharmaceuticals Announces Closing of Private Placement

August 20, 2024

Algernon Pharmaceuticals Announces Increase to Private Placement

August 13, 2024

Algernon Pharmaceuticals Announces Private Placement

Algernon Pharmaceuticals Announces Closing of Private Placement

Algernon Pharmaceuticals Announces Increase to Private Placement

Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil

Algernon Pharmaceuticals Announces Private Placement

Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

January 31, 2024

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

January 11, 2024

Algernon Pharmaceuticals Announces Closing of Private Placement

December 27, 2023

Algernon Pharmaceuticals Announces Increase to Private Placement

December 27, 2023

Profile

Algernon Health Inc is a clinical-stage pharmaceutical development company focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), and stroke, including a program utilizing N,N-Dimethyltryptamine (DMT). Drug re-purposing (also known as re-profiling, re-tasking, or therapeutic switching) involves applying approved drugs and compounds to treat diseases. In addition, the Company is entering the Alzheimer's disease (AD) diagnostic market segment and plans to establish a network of dedicated neuroimaging medical clinics in North America, utilizing FDA-cleared, brain-specific PET scanners to focus on early-stage detection of the disease.